Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 27, 2004; 62 (8) Clinical/Scientific Notes

Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine

Martijn C. Post, Vincent Thijs, Luc Herroelen, Werner I.H.L. Budts
First published April 26, 2004, DOI: https://doi.org/10.1212/01.WNL.0000120756.25236.37
Martijn C. Post
From the Department of Internal Medicine, Division of Cardiology (Drs. Post and Budts), and Department of Neurology (Drs. Thijs and Herroelen), University Hospital Gasthuisberg, Leuven, Belgium.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Thijs
From the Department of Internal Medicine, Division of Cardiology (Drs. Post and Budts), and Department of Neurology (Drs. Thijs and Herroelen), University Hospital Gasthuisberg, Leuven, Belgium.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luc Herroelen
From the Department of Internal Medicine, Division of Cardiology (Drs. Post and Budts), and Department of Neurology (Drs. Thijs and Herroelen), University Hospital Gasthuisberg, Leuven, Belgium.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Werner I.H.L. Budts
From the Department of Internal Medicine, Division of Cardiology (Drs. Post and Budts), and Department of Neurology (Drs. Thijs and Herroelen), University Hospital Gasthuisberg, Leuven, Belgium.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine
Martijn C. Post, Vincent Thijs, Luc Herroelen, Werner I.H.L. Budts
Neurology Apr 2004, 62 (8) 1439-1440; DOI: 10.1212/01.WNL.0000120756.25236.37

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
915

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

A patent foramen ovale (PFO) is one of the major causes of right-to-left shunt, and a causal relationship between migraine and a PFO has been suggested.1 We evaluated whether percutaneous closure of a PFO was associated with changes in the prevalence of migraine.

Methods.

Patient selection.

Patients with a PFO who had a paradoxical embolic event or systemic desaturation and who underwent a percutaneous closure in our center between February 1999 and September 2002 were included. The medical files were reviewed. The ethical committee approved the study.

Evaluation of migraine.

A questionnaire was composed in such a way that a neurologist could diagnose migraine with or without aura (MA+ and MA−) according to the criteria of the International Headache Society. The questionnaire was sent to all patients and focused on three periods: 1 year before and 2 months and at least 6 months after percutaneous closure. Two neurologists blinded to the patients’ files diagnosed MA+ and MA−.

Statistical analysis.

Within-patient comparisons of the absence or presence of migraine were performed with the McNemar’s paired χ2 test. Interobserver reliability was evaluated by measuring the kappa coefficient. p Value < 0.05 was considered significant. All statistical analyses were performed with GB Stat software (version 8.0; Dynamic Microsystems, Inc., Silver Spring, MD).

Results.

Patient characteristics.

Seventy-six patients (mean age, 50.7 ± 12.9 years) were selected, and 66 completed the questionnaire. In 57 patients, the period between PFO closure and completing the questionnaire was >6 months. The characteristics of patients who completed the questionnaire are summarized in the table.

View this table:
  • View inline
  • View popup

Table Characteristics of patients who completed the questionnaire

Prevalence of migraine.

The median time interval between the occurrence of a paradoxical embolic event and the closing procedure was 162 days (range, 0 to 3,613 days). The time between PFO closure and administration of the questionnaire was 579 days (range, 110 to 1,419 days).

Migraine was present in 26 of 66 patients (9 men and 17 women; 39.4%). Twelve (18.2%) had MA+, and 14 (21.2%) had MA−. Two months after closure, the prevalence of MA+ and MA− decreased to 6.1% (4/66) and 6.1% (4/66; p < 0.05 vs before closure). At 6 months or more, the overall prevalence of migraine was 15.8% (9/57; p < 0.05 vs before closure). The prevalences of MA+ and MA− were 5.3% (3/57; p < 0.05 vs before closure) and 10.5% (6/57; p = 0.11 vs before closure). The frequency of migraine attacks also decreased (p < 0.05). Seven patients were taking potential prophylactic migraine drugs 6 months after closure (six, β-blockers; one, calcium antagonists). The kappa coefficient for interobserver reliability for migraine was 0.8 (p < 0.05).

Discussion.

Patients with migraine have a high prevalence of PFO.2 An increased rate of MA+ among stroke patients with PFO was found compared with patients with PFO.2 A causal relationship between PFO and migraine has been proposed. In individuals with a right-to-left shunt, a lower dose of venous trigger substances may be needed to induce migraine because the shunt permits the pulmonary filter to be bypassed.1 Moreover, the prevalence of migraine seems to decrease subsequent to PFO closure in patients with decompression illness.3

We evaluated whether PFO closure in patients who mainly had cryptogenic stroke would be associated with changes in the prevalence of migraine. We found a high rate of migraine in patients with PFO (39.4%) and documented a significant and persistent decrease in prevalence of MA+ ≥6 months after PFO closure. The frequency of migraine attacks also decreased significantly. Our data might fit with the recently reported experience that MA+ decreased after PFO closure.4

The prevalence of migraine also decreases with age; however, we believe that the changes in our study are too pronounced to be explained by the natural history of migraine.5 Most of our patients were treated with low-dose aspirin, which could also influence migraine prophylaxis. The effect of low-dose aspirin, if any, seems to be modest.6 The placebo effect in migraine therapy is potent, but the decrease in prevalence of migraine in our study seems to be larger than reported placebo effect rates of 20 to 40%.7

Nevertheless, this study has important limitations. It is a retrospective, nonrandomized trial of patients selected from a hospital-based database. The questionnaire may be influenced by recall bias.

The prevalence of migraine in patients with a PFO is high. After ≥6 months, percutaneous PFO closure is associated with a decrease in the prevalence of MA+. Whether percutaneous PFO closure has the potential to manage migraine needs to be determined in a prospective randomized trial.

Footnotes

  • See also page 1399

  • Received September 15, 2003.
  • Accepted in final form November 13, 2003.

References

  1. ↵
    Wilmshurst P, Nightingale S. Relationship between migraine and cardiac and pulmonary right-to-left shunts. Clin Sci (Lond). 2001; 100: 215–220.
    OpenUrlCrossRefPubMed
  2. ↵
    Sztajzel R, Genoud D, Roth S, Mermillod B, Le Floch-Rohr J. Patent foramen ovale, a possible cause of symptomatic migraine: a study of 74 patients with acute ischemic stroke. Cerebrovasc Dis. 2002; 13: 102–106.
    OpenUrlCrossRefPubMed
  3. ↵
    Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet. 2000; 356: 1648–1651.
    OpenUrlCrossRefPubMed
  4. ↵
    Morandi E, Anzola GP, Angeli S, Melzi G, Onorato E. Transcatheter closure of patent foramen ovale: a new migraine treatment? J Interv Cardiol. 2003; 16: 39–42.
    OpenUrlCrossRefPubMed
  5. ↵
    Henry P, Auray JP, Gaudin AF, et al. Prevalence and clinical characteristics of migraine in France. Neurology. 2002; 59: 232–237.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Bensenor IM, Cook NR, Lee IM, Chown MJ, Hennekens CH, Buring JE. Low-dose aspirin for migraine prophylaxis in women. Cephalalgia. 2001; 21: 175–183.
    OpenUrlCrossRefPubMed
  7. ↵
    van der Kuy PH, Lohman JJ. A quantification of the placebo response in migraine prophylaxis. Cephalalgia. 2002; 22: 265–270.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Methods.
    • Results.
    • Discussion.
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks

Topics Discussed

  • All Headache
  • Migraine
  • Prevalence studies

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Brief Communications
    Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks
    M. Schwerzmann, S. Wiher, K. Nedeltchev et al.
    Neurology, April 26, 2004
  • Special Article
    Practice advisory update summary: Patent foramen ovale and secondary stroke prevention
    Report of the Guideline Subcommittee of the American Academy of Neurology
    Steven R. Messé, Gary S. Gronseth, David M. Kent et al.
    Neurology, April 29, 2020
  • Articles
    Recurrent cerebral ischemia in medically treated patent foramen ovale
    A meta-analysis
    M. A. Almekhlafi, S. B. Wilton, D. M. Rabi et al.
    Neurology, May 13, 2009
  • Articles
    Prevalence and size of directly detected patent foramen ovale in migraine with aura
    M. Schwerzmann, K. Nedeltchev, F. Lagger et al.
    Neurology, September 07, 2005
Neurology: 100 (13)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise